Zydus Lifesciences pulled up by FDA over quality-control issues
The US health regulator, in a letter to the pharma company, accuses it of violating good manufacturing practices at its Vadodara plant.
15 September, 2024•2 min
0
15 September, 2024•2 min
0
More in Business
Business
Is a revival underway at Asian Paints?
The company’s Q2 results show a belated revival in fortunes, suggesting an aggressive growth path in an industry shaken up by Grasim. The latter is feeling the pressure for the first time ever since it launched its paints business in 2024.
You may also like
Business
Mankind needs to get its mojo back
Once a stock market darling, the pharma company is bearing the brunt of a costly acquisition.
Business
Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
Internet
Why quick delivery of medicines will be difficult to scale
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.
